Monash IVF is the last listed fertility clinic group in its sector after a wave of buyouts, making it a rare, ready-made target for a larger healthcare owner. With strong reimbursement support and room to cut costs and add related services, it could attract private equity or rivals now that a legal cloud has lifted.Read more

This is a micro-cap stock that has barely any sell-side broker coverage, and its core business in providing friction reduction for oil and gas companies in the US will be a big winner given Trump is very pro-oil and gas. However, where we see material value that is under-appreciated by the market is their technology which can treat hazardous man-made chemicals known as Perfluoroalkyl and Polyfluoroalkyl Substances (PFAS).Read more